15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
3 citations
,
September 1998 in “International Journal of Dermatology” Acitretin effectively improved the woman's skin condition.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
August 2022 in “Case reports” Isotretinoin effectively treated a rare scalp condition, but careful drug monitoring and a dairy-free diet were important.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
9 citations
,
January 2021 in “Mediators of Inflammation” 15d‐PGJ2 cream protects against UVB-induced skin damage in mice.
December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
March 2024 in “Journal of cosmetic dermatology” Isotretinoin can effectively reduce symptoms of frontal fibrosing alopecia.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.